// App-Quantinova.ai

519 : Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT.

Researchers

Presenter

  • Marc Peeters

Principal Investigators

  • Tae Won Kim

  • Jin Li

  • Stefano Cascinu

  • Paul Ruff

  • Attili Venkatasatya Suresh

  • Anne Thomas

  • Sergei Tjulandin

  • Xuesong Guan

  • Tien Hoang

  • Yong Jiang Hei

  • Timothy Jay Price

Medical Centers

  • Antwerp University Hospital, Edegem, Belgium

  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of (South), Korea

  • Fudan University Cancer Hospital, Shanghai, China

  • Clinica di Oncologia Medica, Universita Politecnica delle Marche, AO Ospedali Riuniti, Ancona, Italy

  • University of Witwatersrand Faculty of Health Sciences, Johannesburg, South Africa

  • Apollo Hospital, Hyderabad, India

  • Leicester Royal Infirmary Haematology, Leicester, United Kingdom

  • N. N. Blokhin Russian Cancer Research Center, Moscow, Russia

  • Amgen Inc, Thousand Oaks, CA

  • The Queen Elizabeth Hospital, University of Adelaide, Adelaide, Australia

Locations

  • Belgium

  • Republic of South Korea

  • China

  • Italy

  • South Africa

  • India

  • United Kingdom

  • Russia

  • United States

  • Australia

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Colorectal Cancer

Biomarkers

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • Bevacizumab

  • panitumumab

  • Erbitux

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01001377

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved